Hexarelin vs Ipamorelin.

Hexarelin (examorelin) is a synthetic hexapeptide growth hormone secretagogue (GHS), structurally derived from the GHRP-6 family of growth hormone-releasing peptides. It is an investigational compound that was studied in the 1990s and 2000s as a potential agent for probing and stimulating growth hormone secretion and, separately, for direct effects on the heart. It is not an approved drug.

Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) belonging to the growth hormone-releasing peptide (GHRP) class, sometimes described as a "third-generation" GHRP. Derived from the earlier secretagogue GHRP-1, it acts as a ghrelin mimetic and was characterized by Novo Nordisk researchers in the late 1990s as the first GHRP-receptor agonist with selectivity for growth hormone (GH) release approaching that of GHRH. It has no approved therapeutic indication and exists as an investigational/research compound.

Hexarelin acts as an agonist at the growth hormone secretagogue receptor type 1a (GHS-R1a), the same pituitary/hypothalamic receptor activated by the natural hormone ghrelin. Receptor binding engages Gq/11-phospholipase C signaling, mobilizing intracellular calcium in pituitary somatotrophs and triggering pulsatile growth hormone release; this pathway is distinct from and synergistic with GHRH, and also opposes somatostatin tone. Hexarelin additionally binds CD36, a scavenger receptor expressed in cardiac and vascular tissue, which is the proposed basis for GH-independent cardiovascular effects observed in animal models. Because it is a non-selective secretagogue, it also stimulates ACTH/cortisol and prolactin release to a greater degree than more selective agents.

Ipamorelin is a selective agonist of the growth hormone secretagogue receptor type 1a (GHS-R1a), the same G-protein-coupled receptor activated by the endogenous hormone ghrelin. Binding at the pituitary (and hypothalamus) triggers GH release through a GHRP-like pathway distinct from, but synergistic with, GHRH signaling; pharmacological profiling with GHRH and GHRP antagonists showed its action is mediated via the GHRP-type receptor rather than the GHRH receptor. Its defining feature is selectivity: in the original characterization it released GH with potency comparable to GHRP-6 but, unlike older GHRPs, did not meaningfully raise ACTH, cortisol, FSH, LH, prolactin, or TSH, even at doses far above the ED50 for GH release.

Human data exist but are limited to small, short-term, acute physiology studies rather than outcome trials. Acute intravenous hexarelin reliably raised serum growth hormone in healthy volunteers and was compared head-to-head with GH in a controlled human study (Imbimbo/Ghigo group, J Endocrinol Invest 1999, PMID 10342360). Separate small studies reported short-lasting increases in left ventricular ejection fraction and cardiac output in normal subjects, GH-deficient patients, and dilated-cardiomyopathy patients, effects that appeared GH-independent (Bisi/Broglio et al., Endocrine 2001, PMID 11322491). A chronic-administration study found that GH responses desensitized over weeks and characterized effects on the pituitary-adrenal axis and prolactin (Clin Endocrinol 1999, PMID 10341859). Most cardioprotection evidence (CD36-mediated ischemia/reperfusion protection, IL-1 signaling) is preclinical and rodent-based (e.g., Int Heart J 2017, PMID 28321024; review J Geriatr Cardiol 2014, PMID 25278975); none of this advanced to a successful human cardiac outcome trial, and clinical development was discontinued.

The foundational evidence is preclinical: Raun et al. (Eur J Endocrinol, 1998) characterized ipamorelin in rats and isolated pituitary cells, establishing GH selectivity over ACTH/cortisol and other pituitary hormones. Subsequent animal work explored non-endocrine effects via GHS-R1a; for example, Venkova et al. (J Pharmacol Exp Ther, 2009) reported prokinetic/anti-ileus activity in a rodent model of postoperative ileus. The principal human data come from a single industry-sponsored (Helsinn Therapeutics) randomized, double-blind, placebo-controlled proof-of-concept trial in bowel-resection patients (Beck et al., Int J Colorectal Dis, 2014; ClinicalTrials.gov NCT00672074), where the primary composite gastrointestinal-recovery endpoint did not reach statistical significance, though some secondary measures trended favorably. There are no large, controlled human trials demonstrating efficacy for muscle growth, anti-aging, fat loss, bone density, or body composition in people; widely repeated claims in those areas rest on mechanism and animal data, not human outcome trials, and the postoperative-ileus program did not advance to Phase III.

Documented effects in human studies include hexarelin's lack of GH selectivity: it raises cortisol, ACTH, and prolactin alongside growth hormone, so it does not produce a clean GH signal. A well-described limitation is rapid tachyphylaxis/desensitization, with attenuated GH responses on repeated or continuous dosing demonstrated both in vitro (second-messenger level) and over weeks of human administration. Long-term safety in humans is essentially unknown because no large or extended trials were completed; chronic GHS-driven IGF-1 elevation raises theoretical concerns common to this class (fluid retention, insulin sensitivity changes, and the general caution that growth-promoting signaling could be undesirable in the setting of malignancy), but these are not established for hexarelin specifically. There is no established safety profile for non-clinical/self-administered use.

Human safety data are limited to small, short-duration trials; the bowel-resection study used intravenous administration in a hospital setting and did not establish a long-term safety profile. As a GH/IGF-1-axis stimulant, plausible class-related concerns include effects on insulin sensitivity and blood glucose, fluid retention, and theoretical risks tied to chronically elevated GH/IGF-1 (e.g., relevant to people with cancer or active proliferative conditions), though these have not been well characterized for ipamorelin specifically in humans. Because much non-clinical material is produced as unregulated "research chemical" powder, real-world risks also include impurity, mislabeling, and lack of sterility/quality control. Long-term consequences of repeated use in humans are essentially unknown.

Hexarelin is investigational and has never received FDA or EMA marketing approval; its clinical development was discontinued. It is prohibited in sport at all times by WADA as a growth hormone secretagogue / GH-releasing peptide under category S2 of the Prohibited List, and it is generally sold only as a research-use-only chemical.

Ipamorelin is not approved by the FDA (or other major regulators) for any indication; it remains an investigational/research-use compound and was the subject of FDA pharmacy-compounding review activity rather than drug approval. It is prohibited in sport by the World Anti-Doping Agency at all times as a growth hormone secretagogue under category S2 (Peptide Hormones, Growth Factors, and Mimetics).